Eli Lilly and Company (NYSE:LLY) Shares Sold by Stiles Financial Services Inc

Stiles Financial Services Inc lessened its stake in Eli Lilly and Company (NYSE:LLY) by 15.9% in the 1st quarter, Holdings Channel.com reports. The firm owned 2,301 shares of the company’s stock after selling 435 shares during the period. Stiles Financial Services Inc’s holdings in Eli Lilly and Company were worth $1,903,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Garner Asset Management Corp increased its stake in shares of Eli Lilly and Company by 2.3% in the 4th quarter. Garner Asset Management Corp now owns 532 shares of the company’s stock worth $411,000 after acquiring an additional 12 shares during the last quarter. Brighton Jones LLC increased its position in Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC increased its position in Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after purchasing an additional 40 shares during the last quarter. SOA Wealth Advisors LLC. raised its stake in Eli Lilly and Company by 7.1% during the fourth quarter. SOA Wealth Advisors LLC. now owns 925 shares of the company’s stock worth $714,000 after purchasing an additional 61 shares during the period. Finally, Orion Capital Management LLC boosted its holdings in Eli Lilly and Company by 2.5% in the 4th quarter. Orion Capital Management LLC now owns 1,610 shares of the company’s stock valued at $1,243,000 after purchasing an additional 40 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $770.16 on Tuesday. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53. The company has a fifty day simple moving average of $780.81 and a two-hundred day simple moving average of $800.36. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. The company has a market cap of $729.91 billion, a price-to-earnings ratio of 62.67, a price-to-earnings-growth ratio of 1.11 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The company had revenue of $12.73 billion during the quarter, compared to analysts’ expectations of $12.77 billion. During the same quarter last year, the business posted $2.58 earnings per share. The company’s revenue for the quarter was up 45.2% on a year-over-year basis. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.78%. Eli Lilly and Company’s payout ratio is 48.82%.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. HSBC downgraded shares of Eli Lilly and Company from a “buy” rating to a “reduce” rating and cut their price target for the stock from $1,150.00 to $700.00 in a report on Monday, April 28th. Guggenheim reissued a “buy” rating and set a $936.00 target price on shares of Eli Lilly and Company in a research note on Friday. Erste Group Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday, June 5th. Wells Fargo & Company reiterated an “overweight” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Finally, The Goldman Sachs Group raised Eli Lilly and Company from a “neutral” rating to a “buy” rating and cut their price objective for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,011.79.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.